Royal Bank Of Canada started coverage on shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) in a report published on Thursday, MarketBeat reports. The firm issued a sector perform rating and a $6.00 price objective on the biotechnology company’s stock.

Other research analysts have also issued research reports about the company. Zacks Investment Research lowered BioCryst Pharmaceuticals from a hold rating to a sell rating in a report on Tuesday, June 27th. Needham & Company LLC reaffirmed a hold rating on shares of BioCryst Pharmaceuticals in a report on Friday, May 19th. Noble Financial reaffirmed a buy rating on shares of BioCryst Pharmaceuticals in a report on Sunday, May 28th. BidaskClub raised BioCryst Pharmaceuticals from a strong sell rating to a sell rating in a report on Tuesday, August 1st. Finally, ValuEngine lowered BioCryst Pharmaceuticals from a hold rating to a sell rating in a report on Sunday, September 3rd. Two analysts have rated the stock with a sell rating, four have given a hold rating and seven have given a buy rating to the company’s stock. The stock has an average rating of Hold and an average target price of $8.78.

BioCryst Pharmaceuticals (NASDAQ BCRX) opened at 5.15 on Thursday. The firm’s market capitalization is $414.20 million. The company has a 50 day moving average of $4.86 and a 200 day moving average of $6.09. BioCryst Pharmaceuticals has a 1-year low of $3.75 and a 1-year high of $9.25.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.02). BioCryst Pharmaceuticals had a negative return on equity of 276.62% and a negative net margin of 160.97%. The firm had revenue of $3.10 million during the quarter, compared to analysts’ expectations of $5.79 million. During the same period last year, the business posted ($0.22) EPS. The company’s revenue was down 35.4% compared to the same quarter last year. On average, equities research analysts anticipate that BioCryst Pharmaceuticals will post ($0.75) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This news story was originally reported by Daily Political and is the property of of Daily Political. If you are reading this news story on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark legislation. The correct version of this news story can be read at https://www.dailypolitical.com/2017/09/17/biocryst-pharmaceuticals-inc-bcrx-research-coverage-started-at-royal-bank-of-canada.html.

Institutional investors and hedge funds have recently modified their holdings of the company. UBS Asset Management Americas Inc. bought a new stake in shares of BioCryst Pharmaceuticals during the 1st quarter valued at about $392,000. Swiss National Bank boosted its position in shares of BioCryst Pharmaceuticals by 18.7% during the 1st quarter. Swiss National Bank now owns 114,300 shares of the biotechnology company’s stock valued at $960,000 after acquiring an additional 18,000 shares during the last quarter. Bank of New York Mellon Corp boosted its position in shares of BioCryst Pharmaceuticals by 6.8% during the 1st quarter. Bank of New York Mellon Corp now owns 361,289 shares of the biotechnology company’s stock valued at $3,035,000 after acquiring an additional 23,072 shares during the last quarter. Schwab Charles Investment Management Inc. boosted its position in shares of BioCryst Pharmaceuticals by 23.2% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 333,373 shares of the biotechnology company’s stock valued at $2,801,000 after acquiring an additional 62,792 shares during the last quarter. Finally, Emory University bought a new stake in shares of BioCryst Pharmaceuticals during the 1st quarter valued at about $3,153,000. Hedge funds and other institutional investors own 86.23% of the company’s stock.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.

Analyst Recommendations for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Receive News & Ratings for BioCryst Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.